华森制药
(002907)
| 流通市值：45.44亿 | | | 总市值：63.27亿 |
| 流通股本：3.00亿 | | | 总股本：4.18亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 625,912,023.87 | 441,913,009.17 | 238,944,153.42 | 774,819,866.89 |
| 营业收入 | 625,912,023.87 | 441,913,009.17 | 238,944,153.42 | 774,819,866.89 |
| 二、营业总成本 | 557,825,404.58 | 385,855,057.45 | 189,330,193.11 | 699,830,140.66 |
| 营业成本 | 261,503,492.55 | 182,321,137.51 | 97,438,325.28 | 331,050,582.43 |
| 税金及附加 | 8,669,328.67 | 6,985,614.73 | 2,554,236.96 | 12,105,852.91 |
| 销售费用 | 191,208,013.54 | 136,609,078.29 | 68,872,834.62 | 250,533,803.89 |
| 管理费用 | 43,339,930.2 | 28,369,821.76 | 12,696,210.99 | 57,827,627.93 |
| 研发费用 | 59,240,206.24 | 37,041,456.14 | 12,304,890.58 | 59,129,476.89 |
| 财务费用 | -6,135,566.62 | -5,472,050.98 | -4,536,305.32 | -10,817,203.39 |
| 其中:利息费用 | -290,221.62 | 51,406.84 | 1,507.67 | -518,913.86 |
| 其中:利息收入 | 6,072,928.62 | 5,552,157.98 | 4,603,017.85 | 10,321,090.55 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,160,617.85 | 755,500.26 | 471,129.47 | 7,518,348.83 |
| 加:投资收益 | 16,901,273.28 | 15,570,992.36 | -811,330.04 | -6,140,731.36 |
| 资产处置收益 | 8,563,232.58 | - | - | - |
| 资产减值损失(新) | -407,492.6 | -240,732.9 | -86,852.9 | -1,859,620.57 |
| 信用减值损失(新) | -1,133,910.25 | -1,536,386.84 | -2,014,007.51 | -1,635,836.57 |
| 其他收益 | 12,825,780.32 | 4,905,153.01 | 2,348,546.56 | 20,928,702.94 |
| 四、营业利润 | 105,996,120.47 | 75,512,477.61 | 49,521,445.89 | 93,800,589.5 |
| 加:营业外收入 | 157,672.86 | 114,818.51 | 24,571.01 | 208,049.11 |
| 减:营业外支出 | 16,607,704.05 | 13,504,502.66 | 244,679.28 | 566,699.92 |
| 五、利润总额 | 89,546,089.28 | 62,122,793.46 | 49,301,337.62 | 93,441,938.69 |
| 减:所得税费用 | 21,627,956.11 | 9,836,350.44 | 8,946,125.24 | 16,711,713.57 |
| 六、净利润 | 67,918,133.17 | 52,286,443.02 | 40,355,212.38 | 76,730,225.12 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 67,918,133.17 | 52,286,443.02 | 40,355,212.38 | 76,730,225.12 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 72,455,605.89 | 53,950,516.43 | 40,355,212.38 | 76,730,225.12 |
| 少数股东损益 | -4,537,472.72 | -1,664,073.41 | - | - |
| 扣除非经常损益后的净利润 | 52,203,509.88 | 46,754,830.04 | 37,667,440.45 | 51,210,295.72 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.17 | 0.13 | 0.1 | 0.18 |
| (二)稀释每股收益 | 0.17 | 0.13 | 0.1 | 0.18 |
| 八、其他综合收益 | -49,336.4 | -17,736.58 | -6,070.86 | 244,061.74 |
| 归属于母公司股东的其他综合收益 | -49,336.4 | -17,736.58 | -6,070.86 | 244,061.74 |
| 九、综合收益总额 | 67,868,796.77 | 52,268,706.44 | 40,349,141.52 | 76,974,286.86 |
| 归属于母公司股东的综合收益总额 | 72,406,269.49 | 53,932,779.85 | 40,349,141.52 | 76,974,286.86 |
| 归属于少数股东的综合收益总额 | -4,537,472.72 | -1,664,073.41 | - | - |
| 公告日期 | 2025-10-29 | 2025-08-22 | 2025-04-25 | 2025-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |